BILLERICA, Mass, Oct. 3, 2013 /PRNewswire-iReach/ — Aushon Biosystems, a provider of multiplex immunoassay products and services, and Pacific Biomarkers, a leading provider of clinical biomarker laboratory services, have announced today that Pacific Biomarkers has adopted the Cira platform for multiplex biomarker analysis. Pacific Biomarkers will provide enhanced clinical laboratory services, including protocol consultation, sample testing, project management, data management, and customized reporting services to researchers analyzing biomarkers using the Cira platform. “We are excited to offer our pharmaceutical and clinical research clients a new level of comprehensive laboratory services through this agreement with Pacific Biomarkers.” -Susan Vogt, CEO, Aushon BioSystems.
The Cira platform, consisting of the Cirascan™ instrument, Ciraplex™ kits, and Cirasoft™ analysis software, enables simultaneous measurement of up to 12 different proteins, offering significant time savings, cost savings, sample conservation, and enhanced detection of low-abundance proteins compared with traditional analysis methods. “Addition of the Cira platform will strengthen and broaden our biomarker menu in the areas of oncology, pulmonary diseases, cardiovascular diseases, and a wide range of therapeutic areas involving inflammation. The Cira system supports our continued commitment to provide quality biomarker data with new cost-effective platforms.” -Ronald Helm, CEO, Pacific Biomarkers.
Aushon BioSystems, Inc., provides a comprehensive suite of multiplex immunoassay products and services for protein biomarker discovery, development, and analysis to leading pharmaceutical, biotechnology, academic, and diagnostic clients worldwide. Our unique combination of proprietary microarray printing, extensive biomarker content, and innovative Cira immunoassay platform delivers exceptional performance, quality, and reliability to accelerate preclinical and clinical biomarker research. Our customers, who include leading pharmaceutical companies and translational research centers, trust Aushon to supply the most reliable biomarker data available, accelerating the evaluation of potential drug candidates and advancing the use of biomarker profiles in therapeutics.
Pacific Biomarkers is a CAP accredited and CLIA certified biomarker laboratory services provider supporting preclinical and Phase I-IV studies. Since 1989, Pacific Biomarkers has partnered with the Pharmaceutical, Biotech and Diagnostic Manufacturing Industries to provide biomarker laboratory services. Pacific Biomarkers has an established reputation for expertise, flexibility, protocol consultation, and outstanding client services that has propeled the company to a prominent position in the rapidly growing pharmaceutical outsourcing industry. With an extensive network of scientific, regulatory, and technology expertise, Pacific Biomarkers is the service provider of choice for many leading international drug manufacturers in the race to bring products to market as quickly and cost effectively as possible.
Media Contact: Bill Williams, Aushon BioSystems, Inc., 978-436-6400, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Aushon BioSystems, Inc.